Crossmark

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial

Crossref DOI link: https://doi.org/10.1007/s10928-026-10038-7

Published Online: 2026-06-04

Published Print: 2026-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Yibo

Hadigol, Mark

Lincha, Victor Ruberio

Hoffman, Justin

Azad, Arun A.

Agarwal, Neeraj

Matsubara, Nobuaki

Zohren, Fabian

DeAnnuntis, Liza

Wang, Diane D.
License Information

Text and Data Mining valid from 2026-06-04

Version of Record valid from 2026-06-04
More Information

Article History

Received: 17 June 2025

Accepted: 23 April 2026

First Online: 4 June 2026

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below